Singapore markets closed

Eupraxia Pharmaceuticals Inc. (EPRX.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
2.6600+0.1100 (+4.31%)
At close: 3:29PM EDT

Eupraxia Pharmaceuticals Inc.

2067 Cadboro Bay Road
Suite 201
Victoria, BC V8R 5G4
Canada
250 590 3968
http://www.eupraxiapharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees

Key executives

NameTitlePayExercisedYear born
Dr. James A. HelliwellCEO & DirectorN/AN/A1974
Mr. Bruce G. Cousins CPA, C.A., CPAPres & CFON/AN/A1961
Dr. Amanda Malone Ph.D.Chief Scientific OfficerN/AN/A1981
Mr. Alexander John Rothwell Eng., M.B.A.AdvisorN/AN/A1969
Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis, as well as under development for treating canine and equine osteoarthritis. Its products in development also include EP-201, an antibiotic for post-surgical site infections; and EP-105, an extended-release post-surgical anesthetic for post-surgical pain. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.

Corporate governance

Eupraxia Pharmaceuticals Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.